verdinexor
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02431364)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Exportin-1INHIBITOR
XPO1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1ccccn1- Mol. weight
- 442.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545187 ↗
Also known as
- kpt-335
- kpt-335
- kpt-335
- verdinexor
- verdinexor
- verdinexor
- verdinexor
- verdinexor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02431364 | Phase 1 | May 1, 2015 | Karyopharm Therapeutics Inc, Nucleus Network Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | For profit | 1 | 1 | 1 | 2015 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1